BX795, a TBK1 inhibitor, exhibits antitumor activity in human oral squamous cell carcinoma through apoptosis induction and mitotic phase arrest

European Journal of Pharmacology

Volumn 769, Issue , 2015, Pages 287-296

  Bai, Li Yuan ^a,d   Chiu, Chang Fang ^a,d   Kapuriya, Naval P ^b   Shieh, Tzong Ming ^c   Tsai, Yu Chen ^c   Wu, Chia Yung ^c   Sargeant, Aaron M ^e   Weng, Jing Ru ^c  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Shree M and N Virani Science College   (India)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHARLES RIVER LABORATORIES   (United States)

Author keywords

Autophagy; BX795; Cell cycle; Oral cancer; TBK1

Indexed keywords

ANTINEOPLASTIC AGENT; BX 795; MEMBRANE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; PROTEIN P62; TANK BINDING KINASE 1; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG; BX795; I KAPPA B KINASE; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; PYRIMIDINE DERIVATIVE; TBK1 PROTEIN, HUMAN; THIOPHENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA FRAGMENTATION; ELECTROPHORESIS; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KERATINOCYTE; MITOSIS; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; MOUTH TUMOR; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CARCINOMA, SQUAMOUS CELL; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; I-KAPPA B KINASE; MITOSIS; MOUTH NEOPLASMS; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; SIGNAL TRANSDUCTION; THIOPHENES;

EID: 84948969044     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.11.032     Document Type: Article

References (38)

1. L.Y. Bai, W.Y. Lin, C.F. Chiu, and J.R. Weng Anti-tumor activities of triterpenes from Syzygium kusukusense Nat. Prod. Commun. 9 2014 1557 1558
2. L.Y. Bai, J.R. Weng, C.F. Chiu, C.Y. Wu, S.P. Yeh, A.M. Sargeant, P.H. Lin, and Y.M. Liao OSU-A9, an indole-3-carbinol derivative, induces cytotoxicity in acute myeloid leukemia through reactive oxygen species-mediated apoptosis Biochem. Pharmacol. 86 2013 1430 1440
3. L.Y. Bai, J.R. Weng, J.L. Hu, D. Wang, A.M. Sargeant, and C.F. Chiu G15, a GPR30 antagonist, induces apoptosis and autophagy in human oral squamous carcinoma cells Chem. Biol. Interact. 206 2013 375 384
4. J. Bain, L. Plater, M. Elliott, N. Shpiro, C.J. Hastie, H. McLauchlan, I. Klevernic, J.S. Arthur, D.R. Alessi, and P. Cohen The selectivity of protein kinase inhibitors: a further update Biochem. J. 408 2007 297 315
5. D.A. Barbie, P. Tamayo, J.S. Boehm, S.Y. Kim, S.E. Moody, I.F. Dunn, A.C. Schinzel, P. Sandy, E. Meylan, C. Scholl, S. Frohling, E.M. Chan, M.L. Sos, K. Michel, C. Mermel, S.J. Silver, B.A. Weir, J.H. Reiling, Q. Sheng, P.B. Gupta, R.C. Wadlow, H. Le, S. Hoersch, B.S. Wittner, S. Ramaswamy, D.M. Livingston, D.M. Sabatini, M. Meyerson, R.K. Thomas, E.S. Lander, J.P. Mesirov, D.E. Root, D.G. Gilliland, T. Jacks, and W.C. Hahn Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 Nature 462 2009 108 112
6. W. Chaabane, S.D. User, M. El-Gazzah, R. Jaksik, E. Sajjadi, J. Rzeszowska-Wolny, and M.J. Los Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer Arch. Immunol. Ther. Exp. 61 2013 43 58
7. Y. Chien, S. Kim, R. Bumeister, Y.M. Loo, S.W. Kwon, C.L. Johnson, M.G. Balakireva, Y. Romeo, L. Kopelovich, M. Gale Jr., C. Yeaman, J.H. Camonis, Y. Zhao, and M.A. White RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival Cell 127 2006 157 170
8. S.H. Chiou, C.C. Yu, C.Y. Huang, S.C. Lin, C.J. Liu, T.H. Tsai, S.H. Chou, C.S. Chien, H.H. Ku, and J.F. Lo Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma Clin. Cancer Res. 14 2008 4085 4095
9. K. Clark, L. Plater, M. Peggie, and P. Cohen Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation J. Biol. Chem. 284 2009 14136 14146
10. E.C. Dees, R.B. Cohen, M. von Mehren, T.E. Stinchcombe, H. Liu, K. Venkatakrishnan, M. Manfredi, H. Fingert, H.A. Burris 3rd, and J.R. Infante Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations Clin. Cancer Res. 18 2012 4775 4784
11. C. Didelot, M. Barberi-Heyob, A. Bianchi, P. Becuwe, J.F. Mirjolet, M. Dauca, and J.L. Merlin Constitutive NF-kappaB activity influences basal apoptosis and radiosensitivity of head-and-neck carcinoma cell lines Int. J. Radiat. Oncol. Biol. Phys. 51 2001 1354 1360
12. R.I. Feldman, J.M. Wu, M.A. Polokoff, M.J. Kochanny, H. Dinter, D. Zhu, S.L. Biroc, B. Alicke, J. Bryant, S. Yuan, B.O. Buckman, D. Lentz, M. Ferrer, M. Whitlow, M. Adler, S. Finster, Z. Chang, and D.O. Arnaiz Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1 J. Biol. Chem. 280 2005 19867 19874
13. K.A. Fitzgerald, S.M. McWhirter, K.L. Faia, D.C. Rowe, E. Latz, D.T. Golenbock, A.J. Coyle, S.M. Liao, and T. Maniatis IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway Nat. Immunol. 4 2003 491 496
14. M.A. Hardwicke, C.A. Oleykowski, R. Plant, J. Wang, Q. Liao, K. Moss, K. Newlander, J.L. Adams, D. Dhanak, J. Yang, Z. Lai, D. Sutton, and D. Patrick GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models Mol. Cancer Ther. 8 2009 1808 1817
15. E.C. Hsu, S.K. Kulp, H.L. Huang, H.J. Tu, S.B. Salunke, N.J. Sullivan, D. Sun, M.S. Wicha, C.L. Shapiro, and C.S. Chen Function of integrin-linked kinase in modulating the stemness of IL-6-abundant breast cancer cells by regulating gamma-secretase-mediated notch1 activation in caveolae Neoplasia 17 2015 497 508
16. J.K. Kim, Y. Jung, J. Wang, J. Joseph, A. Mishra, E.E. Hill, P.H. Krebsbach, K.J. Pienta, Y. Shiozawa, and R.S. Taichman TBK1 regulates prostate cancer dormancy through mTOR inhibition Neoplasia 15 2013 1064 1074
17. C. Korherr, H. Gille, R. Schafer, K. Koenig-Hoffmann, J. Dixelius, K.A. Egland, I. Pastan, and U. Brinkmann Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway Proc. Natl. Acad. Sci. USA 103 2006 4240 4245
18. A. Kumar, Y. Takada, A.M. Boriek, and B.B. Aggarwal Nuclear factor-kappaB: its role in health and disease J. Mol. Med. 82 2004 434 448
19. J. Li, J. Huang, J.H. Jeong, S.J. Park, R. Wei, J. Peng, Z. Luo, Y.T. Chen, Y. Feng, and J.L. Luo Selective TBK1/IKKi dual inhibitors with anticancer potency Int. J. Cancer 134 2014 1972 1980
20. J. Lim, J.H. Kim, J.Y. Paeng, M.J. Kim, S.D. Hong, J.I. Lee, and S.P. Hong Prognostic value of activated Akt expression in oral squamous cell carcinoma J. Clin. Pathol. 58 2005 1199 1205
21. S.C. Lin, S.Y. Lu, S.Y. Lee, C.Y. Lin, C.H. Chen, and K.W. Chang Areca (betel) nut extract activates mitogen-activated protein kinases and NF-kappaB in oral keratinocytes Int. J. Cancer 116 2005 526 535
22. H.H. Lu, C.J. Liu, T.Y. Liu, S.Y. Kao, S.C. Lin, and K.W. Chang Areca-treated fibroblasts enhance tumorigenesis of oral epithelial cells J. Dent. Res. 87 2008 1069 1074
23. M. Lun, P.L. Zhang, P.K. Pellitteri, A. Law, T.L. Kennedy, and R.E. Brown Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB Ann. Clin. Lab. Sci. 35 2005 251 258
24. R. Mathew, V. Karantza-Wadsworth, and E. White Role of autophagy in cancer Nat. Rev. Cancer 7 2007 961 967
25. R. Mehra, I.G. Serebriiskii, B. Burtness, I. Astsaturov, and E.A. Golemis Aurora kinases in head and neck cancer Lancet Oncol. 14 2013 e425 e435
26. H. Nakayama, T. Ikebe, M. Beppu, and K. Shirasuna High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity Cancer 92 2001 3037 3044
27. C. Pan, M. Yan, J. Yao, J. Xu, Z. Long, H. Huang, and Q. Liu Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells Oral Oncol. 44 2008 639 645
28. G. Qi, I. Ogawa, Y. Kudo, M. Miyauchi, B.S. Siriwardena, F. Shimamoto, M. Tatsuka, and T. Takata Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer Virchows Arch. 450 2007 297 302
29. K.M. Rahman, S. Ali, A. Aboukameel, S.H. Sarkar, Z. Wang, P.A. Philip, W.A. Sakr, and A. Raz Inactivation of NF-kappaB by 3,3′-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells Mol. Cancer Ther. 6 2007 2757 2765
30. A.O. Rehman, and C.Y. Wang CXCL12/SDF-1 alpha activates NF-kappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex Int. J. Oral Sci. 1 2009 105 118
31. S.A. Schwartz, A. Hernandez, and B. Mark Evers The role of NF-kappaB/IkappaB proteins in cancer: implications for novel treatment strategies Surg. Oncol. 8 1999 143 153
32. S. Sharma, B.R. tenOever, N. Grandvaux, G.P. Zhou, R. Lin, and J. Hiscott Triggering the interferon antiviral response through an IKK-related pathway Science 300 2003 1148 1151
33. R.R. Shen, and W.C. Hahn Emerging roles for the non-canonical IKKs in cancer Oncogene 30 2011 631 641
34. T. Tamatani, M. Azuma, K. Aota, T. Yamashita, T. Bando, and M. Sato Enhanced IkappaB kinase activity is responsible for the augmented activity of NF-kappaB in human head and neck carcinoma cells Cancer Lett. 171 2001 165 172
35. E. Tasdemir, M.C. Maiuri, I. Orhon, O. Kepp, E. Morselli, A. Criollo, and G. Kroemer p53 represses autophagy in a cell cycle-dependent fashion Cell Cycle 7 2008 3006 3011
36. L.L. Tsai, C.C. Yu, Y.C. Chang, C.H. Yu, and M.Y. Chou Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma J. Oral Pathol. Med. 40 2011 621 628
37. J.B. Vermorken, E. Remenar, C. van Herpen, T. Gorlia, R. Mesia, M. Degardin, J.S. Stewart, S. Jelic, J. Betka, J.H. Preiss, D. van den Weyngaert, A. Awada, D. Cupissol, H.R. Kienzer, A. Rey, I. Desaunois, J. Bernier, and J.L. Lefebvre Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N. Engl. J. Med. 357 2007 1695 1704
38. J. Yao, L. Duan, M. Fan, and X. Wu NF-kappaB signaling pathway is involved in growth inhibition, G2/M arrest and apoptosis induced by Trichostatin A in human tongue carcinoma cells Pharmacol. Res. 54 2006 406 413